MedPath

Tagged News

Raina Biosciences Publishes Breakthrough AI Platform for mRNA Therapeutics in Science

AICAR-TDrug Discovery
  • Raina Biosciences announced publication of its GEMORNA platform data in Science, marking the world's first generative AI platform purpose-built for mRNA design and optimization.
  • GEMORNA-generated mRNAs demonstrated up to 150-fold increase in human erythropoietin expression and nearly 100% anti-tumor efficacy in primary human T cells compared to benchmarks.
  • The MIT spinout company closed a $5.7 million angel round and is collaborating with leading pharmaceutical and biotech companies to accelerate mRNA therapeutic development.
  • The platform addresses key limitations in mRNA therapeutics by designing sequences with enhanced expression levels and durability across diverse therapeutic applications.

IQVIA and Flagship Pioneering Form Strategic Alliance to Accelerate Biotech Innovation Through AI-Powered Drug Development

AI
  • IQVIA and Flagship Pioneering announced a strategic collaboration in August 2025 to accelerate breakthrough life sciences companies using AI-powered analytics and clinical trial expertise.
  • The partnership focuses on three core areas: drug development strategy and analytics, clinical development, and asset valuation and due diligence for Flagship's 40+ biotech portfolio companies.
  • IQVIA's deployment of over 50 NVIDIA-built AI agents trained on 1.2 billion health records aims to reduce patient recruitment bottlenecks and accelerate clinical trial timelines.
  • The collaboration leverages Flagship's $14 billion in assets under management and IQVIA's $32.1 billion R&D backlog to enhance commercial viability of emerging biotech ventures.

Cleveland Clinic Deploys AI Platform to Accelerate Clinical Trial Recruitment Across Multiple Specialties

AIRare Disease
  • Cleveland Clinic has launched Dyania Health's Synapsis AI platform across its clinical research enterprise following successful pilot programs in cardiology, oncology, and neurology.
  • The AI platform identified melanoma trial patients in 2.5 minutes with 96% accuracy, dramatically outperforming specialized nurses who required over 400 minutes for similar accuracy.
  • For a rare heart disease trial, the system screened 1.2 million records and identified 30 eligible participants in one week, compared to 14 patients found through routine methods over 90 days.
  • The collaboration addresses critical recruitment challenges where 80% of clinical trials miss enrollment timelines and 50% of trial sites fail to recruit any participants.

Circurna Partners with GATC Health to Accelerate Circular RNA Therapeutics Using AI Platform

AIDrug Discovery
  • Circurna and GATC Health announced a strategic partnership to apply advanced AI technology for optimizing circular RNA therapeutics development.
  • The collaboration will leverage GATC's AI platform to enhance lipid nanoparticle designs, targeting ligands, and payload candidates for Circurna's ciRNA platform.
  • Circular RNA offers enhanced stability and protein expression compared to traditional mRNA, positioning it as a next-generation therapeutic modality.
  • GATC Health will receive cash, equity compensation, and milestone-based payments as part of the agreement terms.

Verily Shuts Down Medical Device Program as Alphabet Pivots to AI-Driven Healthcare Strategy

AI
  • Alphabet's life sciences subsidiary Verily eliminated its entire medical device program and laid off staff as part of a strategic shift toward AI and data infrastructure.
  • CEO Stephen Gillett announced the closure in a staff memo, acknowledging Verily's legacy in developing innovative medical devices while emphasizing the need for difficult decisions.
  • The shutdown reflects Alphabet's broader cost-cutting measures and aggressive investment in AI technology following the generative AI boom that began in early 2023.
  • This strategic pivot represents a significant change in Alphabet's healthcare approach, moving away from hardware development toward AI-powered solutions.

Singapore's Nanyang Biologics Partners with Tech Giants to Accelerate AI-Powered Drug Discovery Platform

AIDrug Discovery
  • Nanyang Biologics has partnered with Equinix, Hewlett Packard Enterprise, and Nvidia to develop Vecura, an AI-enabled drug discovery platform that can identify potential drug candidates in as little as six minutes by 2026.
  • The platform builds on the company's earlier DTIGN technology, which successfully identified 15 potential drug candidates within six months for a Japanese pharmaceutical firm using graph neural networks and a library of compounds from over 50,000 organisms.
  • The global drug discovery platform market is projected to grow from $186 million in 2024 to $635 million by 2034, representing a compound annual growth rate of over 13 percent.
  • This collaboration positions Singapore as a leading hub for AI-enabled drug discovery, with Nanyang Biologics planning to commercialize the platform for other pharmaceutical companies while retaining intellectual property ownership.

Proxygen Partners with EPFL to Advance AI-Driven Molecular Glue Degrader Discovery

AIDrug Discovery
  • Proxygen, a leader in molecular glue degrader discovery, has announced a strategic research collaboration with EPFL to integrate AI-driven computational design with high-throughput screening platforms.
  • The partnership combines Proxygen's validated glue degrader discovery platform with Professor Bruno Correia's pioneering work in AI and structural modeling for protein design and therapeutic discovery.
  • The collaboration aims to systematically predict and validate neosubstrate-ligase interactions and design chemical matter capable of inducing targeted protein degradation across previously inaccessible target space.
  • This integrated approach is expected to accelerate glue degrader development with greater precision and scale, building on Proxygen's existing partnerships with major pharmaceutical companies including Merck KGaA and Merck & Co Inc.

Zephyr AI Names Watson Pharmaceuticals Founder Dr. Allen Chao as CEO, Acquires Aster Insights to Accelerate Cancer Drug Development

AIPrecision MedicineReal World EvidenceOncology
  • Zephyr AI has appointed Dr. Allen Chao, founder of Watson Pharmaceuticals, as Chief Executive Officer, bringing over 40 years of biopharmaceutical leadership experience.
  • The company simultaneously acquired Aster Insights, gaining access to the world's largest observational cancer study dataset with over 400,000 lifetime-consented patients.
  • The combined entity creates a formidable real-world evidence platform that integrates AI-driven precision medicine with comprehensive genomic, clinical, and transcriptome data.
  • Integration efforts are already underway focusing on biomarker discovery, clinical trial optimization, and AI-enabled companion diagnostics development.

Expecto Health Science Partners with VertisPro to Deploy AI-Driven Patient Recruitment in Asia-Pacific Clinical Trials

AI
  • Expecto Health Science, an Asia-Pacific Contract Research Organisation, has announced a strategic collaboration with VertisPro to integrate AI-driven patient acquisition solutions into clinical trials.
  • The partnership aims to address patient recruitment challenges in rare disease and oncology trials by improving patient identification accuracy and shortening recruitment timelines.
  • VertisPro's artificial intelligence platform will be integrated into Expecto's service offerings to help sponsors achieve better trial enrollment success rates across the region.
  • The collaboration combines Expecto's clinical operations expertise with VertisPro's proven recruitment technology to accelerate patient access to innovative therapies.

Tempus AI Acquires Paige to Build World's Largest Oncology Foundation Model

AIPrecision MedicineOncologyDrug Discovery
  • Tempus AI has acquired Paige, an AI company specializing in digital pathology with FDA-cleared cancer detection applications and nearly 7 million digitized pathology slides.
  • The $81.25 million stock acquisition positions Tempus to build the largest oncology foundation model in history by combining datasets and AI capabilities.
  • The strategic move strengthens Tempus' position in the digital pathology market projected to reach $10 billion by 2030, enhancing drug discovery and personalized medicine capabilities.
  • Paige's global dataset from 45 countries and partnership with Memorial Sloan Kettering Cancer Center adds significant credibility and diversity to Tempus' AI platform.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.